Cardiovascular effectiveness was observed, largely independent of age, in a cohort of older patients with type 2 diabetes.

A major new study finds that certain diabetes medications, including GLP-1 and SGLT2 inhibitors, may be linked to a reduced ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

GLP-1 receptor agonists were associated with improved survival and reduced graft loss among kidney transplant recipients with type 2 diabetes.

Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to inhibit the enzyme has been explored. Several DPP-4 inhibitors are in clinical development; these are ...

25). The trial is the first to test the cardiovascular benefits of an oral GLP-1 inhibitor. Both injectable and oral forms of semaglutide are already approved by the U.S. Food and Drug ...